# US 2025/0320302 A1 · Interferon-associated antigen binding proteins for use for the treatment or prevention of coronavirus infection

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0320302 A1
- Document ID: US20250320302A1
- Status: Published application
- Kind: A1
- Application number: 18/568,017
- Filed: 2022-06-08
- Published: 2025-10-16
- Earliest claimed: 2021-06-09
- Assignees: Evotec International GmbH
- Applicants: Evotec International GmbH
- Inventors: Kara CARTER; Grégory Kévin Jean-René NEVEU; Marion Rachel France DAJON; Xavier MARNIQUET; Antoine ALAM
- Web page: https://patentgrep.com/patent/US20250320302A1

## CPC

- C07K 16/2878: {against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95}
- A61P 31/14: for RNA viruses
- C07K 14/555: Interferons [IFN]
- C07K 14/56: IFN-alpha
- C07K 14/565: IFN-beta
- A61K 2039/505: {comprising antibodies}
- C07K 2317/52: Constant or Fc region; Isotype
- C07K 2317/75: Agonist effect on antigen
- C07K 2317/92: Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C07K 2319/00: Fusion polypeptide
- C07K 2319/33: fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
- C07K 2319/74: containing a fusion for binding to a cell surface receptor
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The present invention relates to methods for treating or preventing Coronavirus infection in a subject by administering a combination of a tumor necrosis factor receptor superfamily (TNFRSF) agonist and an interferon (IFN), for example an IFN-associated antigen binding protein, such as an IFN-fused antibody, or nucleic acids and expression vectors coding therefor. The present invention also relates to the use of corresponding pharmaceutical compositions for use in treating Coronavirus infection.

## Claims

### Claim 1

A combination of a tumor necrosis factor receptor superfamily (TNFRSF) agonist or a functional fragment thereof and an interferon (IFN) or a functional fragment thereof, for use in the treatment or prevention of a Coronavirus infection.

### Claim 2

An interferon-associated antigen binding protein comprising
(I) an agonistic anti-CD40 antibody or an agonistic antigen binding fragment thereof, and
(II) an Interferon (IFN) or a functional fragment thereof
for use in the treatment or prevention of a Coronavirus infection.

### Claim 3 (depends on 2)

The interferon-associated antigen binding protein for the use of claim 2, wherein the agonistic anti-CD40 antibody or the agonistic antigen binding fragment thereof comprises
(a) a heavy chain or a fragment thereof comprising a complementarity determining region (CDR) CDRH1 that is at least 90% identical to SEQ ID NO 56, a CDRH2 that is at least 90% identical to SEQ ID NO 57, and a CDRH3 that is at least 90% identical to SEQ ID NO 58; and
(b) a light chain or a fragment thereof comprising a CDRL1 that is at least 90% identical to SEQ ID NO 52, a CDRL2 that is at least 90% identical to SEQ ID NO 53, and a CDRL3 that is at least 90% identical to SEQ ID NO 54.

### Claim 4 (depends on 2)

The interferon-associated antigen binding protein for the use of claim 2, wherein the agonistic anti-CD40 antibody or the agonistic antigen binding fragment thereof comprises
(a) a heavy chain or a fragment thereof comprising a complementarity determining region (CDR) CDRH1 that is identical to SEQ ID NO 56, a CDRH2 that is identical to SEQ ID NO 57, and a CDRH3 that is identical to SEQ ID NO 58; and
(b) a light chain or a fragment thereof comprising a CDRL1 that is identical to SEQ ID NO 52, a CDRL2 that is identical to SEQ ID NO 53, and a CDRL3 that is identical to SEQ ID NO 54.

### Claim 5 (depends on 2)

The interferon-associated antigen binding protein for the use of claim 2, wherein the agonistic anti-CD40 antibody, or the agonistic antigen binding fragment thereof, comprises a light chain variable region VL comprising the sequence as set forth in SEQ ID NO 51, or a sequence at least 90% identical thereto; and/or a heavy chain variable region VH comprising the sequence as set forth in SEQ ID NO 55, or a sequence at least 90% identical thereto.

### Claim 6 (depends on 2)

The interferon-associated antigen binding protein for the use of claim 2, wherein the agonistic anti-CD40 antibody or the agonistic antigen binding fragment thereof comprises a light chain (LC) that comprises a sequence as set forth in SEQ ID NO 3, or a sequence at least 90% identical thereto; and/or a heavy chain (HC) that comprises a sequence selected from the group consisting of SEQ ID NO 6, SEQ ID NO 9, SEQ ID NO 49 and SEQ ID NO 48, or a sequence at least 90% identical thereto.

### Claim 7 (depends on 2)

The interferon-associated antigen binding protein for the use of claim 2, wherein the IFN or the functional fragment thereof is selected from the group consisting of a Type I IFN, a Type II IFN and a Type III IFN, or a functional fragment thereof.

### Claim 8 (depends on 7)

The interferon-associated antigen binding protein for the use of claim 7, wherein the type I IFN or the functional fragment thereof is IFNα or IFNβ, or a functional fragment thereof.

### Claim 9 (depends on 2)

The interferon-associated antigen binding protein for the use of claim 2, wherein the IFN or the functional fragment thereof is IFNα2a, or a functional fragment thereof, and wherein preferably the IFNα2a comprises the sequence as set forth in SEQ ID NO 17, or a sequence at least 90% identical thereto.

### Claim 10 (depends on 2)

The interferon-associated antigen binding protein for the use of claim 2, wherein the IFN or the functional fragment thereof is IFNβ, or a functional fragment thereof, and wherein preferably the IFNβ comprises the sequence as set forth in SEQ ID NO 14, or a sequence at least 90% identical thereto.

### Claim 11 (depends on 2)

The interferon-associated antigen binding protein for the use of claim 2, wherein the IFN or the functional fragment thereof is fused to a light chain of the agonistic anti-CD40 antibody or the agonistic antigen binding fragment thereof, preferably to the C-terminus.

### Claim 12 (depends on 2)

The interferon-associated antigen binding protein for the use of claim 2, wherein the IFN or the functional fragment thereof is fused to a heavy chain of the agonistic anti-CD40 antibody or the agonistic antigen binding fragment thereof, preferably to the C-terminus.

### Claim 13 (depends on 2)

The interferon-associated antigen binding protein for the use of claim 2, wherein the agonistic anti-CD40 antibody or an agonistic antigen binding fragment thereof, and the IFN or the functional fragment thereof, are fused to each other via a linker, and wherein preferably the linker comprises a sequence as set forth in SEQ ID NO 20, SEQ ID NO 21, SEQ ID NO 24, SEQ ID NO 25 or SEQ ID NO 26.

### Claim 14 (depends on 2)

The interferon-associated antigen binding protein for the use of claim 2, wherein the interferon-associated antigen binding protein is an interferon-fused agonistic anti-CD40 antibody or an interferon-fused agonistic antigen binding fragment thereof comprising one of the sequence combinations disclosed in Table 9, in particular Table 9A or Table 9B, more particularly Table 9A.

### Claim 15 (depends on 2)

The interferon-associated antigen binding protein for the use of claim 2, wherein the use comprises administering the interferon-associated antigen binding protein to a subject in need thereof by means of genetic delivery with RNA or DNA sequences encoding the interferon-associated antigen binding protein, or a vector or vector system encoding the interferon-associated antigen binding protein.

### Claim 16 (depends on 2)

The interferon-associated antigen binding protein for the use of claim 2, wherein the interferon-associated antigen binding protein is comprised in a pharmaceutical composition.
